Novo Nordisk Launches DKK 15 Billion Share Buyback Over 12 Months
Novo Nordisk initiated a share repurchase programme of up to DKK 15 billion over a 12-month period beginning 4 February 2026 under EU Safe Harbour rules. Its phase III CLEOPATTRA trial of coramitug, acquired from Prothena, could generate up to $1.23 billion in milestones as a late-stage amyloid therapy candidate.
1. Share Repurchase Programme Details
Novo Nordisk initiated on 4 February 2026 a share repurchase programme under MAR Article 5 of Regulation 596/2014 and Commission Delegated Regulation (EU) 2016/1052 (Safe Harbour rules), authorizing up to DKK 15 billion in buybacks over a 12-month period.
2. Impact on Capital Allocation
The programme is designed to enhance shareholder returns through share count reduction and support for earnings per share, with flexibility to execute repurchases in response to market conditions and capital allocation priorities.
3. Phase III Coramitug Collaboration
Novo Nordisk is advancing coramitug in the phase III CLEOPATTRA trial for ATTR cardiomyopathy, a candidate acquired from Prothena that could deliver up to $1.23 billion in development and sales milestone payments.